LineaRx provides large-scale production of DNA sequences using polymerase chain reaction (PCR). LineaRx is an Applied DNA Sciences subsidiary.
LineaRx is collaborating with Takis Biotech to develop linear DNA vaccine candidates as treatments for coronavirus. This research effort will use a Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. One of the vaccine candidates will be based on the entire spike gene of the coronavirus, while the remaining will be designed based on the antigenic portions of the protein.